COVID-19 Treatment

Therapeutic Treatment Options for COVID-19 Patients

Monoclonal Antibody Treatment

COVID-19 treatments are available that may help reduce the risk of hospitalization and serious complications for eligible high-risk people who test positive for COVID-19. Called monoclonal antibody treatments, the treatments are most beneficial when given as soon as possible after an individual tests positive for COVID.

Monoclonal antibody treatments are available through the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for non-hospitalized COVID-19 positive people.

WHO QUALIFIES?

• CHART: Clinical Pathway showing eligibility for COVID-19 monoclonal antibody therapy. (Updated 04/14/2021)

FIND TREATMENT:

• See your health care provider for a treatment referral to a North Dakota health care facility that provides monoclonal antibody treatment. 

• MAP: Health care facilities providing monoclonal antibody treatment

  • Hospitals with the “red H” indicates that no outpatient therapies are provided.

  • Hospitals with the “blue H” indicates that outpatient therapies are provided. 

NOTE: The following web content was created by the Minnesota Department of Health and is used with their permission in the interest of public health.

General Resources

• GENERAL INFO: HHS: Monoclonal Antibodies for High-Risk COVID-19 Positive Patients
  General information on monoclonal antibody treatments and other COVID-19 treatment options.
• FAQ: Monoclonal Antibody Treatment: Frequently Asked Questions (MNDoH)
  Updated 04/21/21
• INFUSION CENTER LOCATOR: National Infusion Center Association: COVID-19 Monoclonal Antibody Infusion Center Locator
  Infusion sites displayed in this tool have been authorized to administer antibody treatments for COVID-positive patients under Emergency Use Authorization, but their inclusion in this tool does not imply current availability of doses.

These antibody therapies are restricted to certain high-risk patients and require a drug order (similar to a prescription) from a Health Care Provider (HCP) for eligible patients. HCPs must verify eligibility of their patients and verify the availability of doses at an authorized infusion site before they refer an eligible patient to schedule an appointment to receive treatment at an authorized infusion site.
If you have difficulty navigating the site, please see the National Infusion Center Association COVID-19 Antibody Treatment: Resource Center.

• CMS: Insurance Coverage of Monoclonal Antibody Treatment
  Information on Medicare, Medicaid/CHIP, and plans subject to ACA market reforms.
• CMS: Medicare Monoclonal Antibody Infusion Program Instructions
  Information for health care providers on Medicare payment, billing and coding for monoclonal antibody treatment.

Bamlanivimab (BAM) and Etesevimab (together)

• Emergency Use Authorization of Bamlanivimab and Etesevimab
  Fact sheet for patients
  02/09/2021
• Update: FDA revokes emergency use authorization for Bamlanivimab when administered alone
  (Alternative monoclonal antibody therapies remain available) 04/16/2021​​​​​​​

Regeneron - Casirivimab and Imdevimab

• Regeneron: Casirivimab and Imdevimab EUA Guidebook (PDF)
  Product information for providers and infusion sites.
• Regeneron: Authorized for FDA Emergency Use only Casirivimab and Imdevimab
  Website of the manufacturer of casirivimab and imdevimab. See additional links, resources, and guidance to facilities administering the treatment, including:
  • FDA letter of authorization
  • Fact sheet for U.S. health care providers
  • Fact sheet for patients and caregivers in English and Spanish
  • Dear Healthcare Provider letter (prescribing information)
  • Information on packaging and preparation of casirivimab and imdevimab

For other questions, please contact the North Dakota Department of Health (NDDoH) COVID hotline at 1-866-207-2880. 

SOURCE: MN Dept. of Health website, www.health.state.mn.us/diseases/coronavirus/meds.html